Society for Neuroscience - Search

Skip Navigation

  • join logo Join
  • hands shaped like a yellow heart icon Give
  • advocate logo Advocate
  • publish logo Publish
  • Icon with thought bubbles Learn
Shop Sign In
SfN Logo 2025
  • Membership
    • Learn About Membership
      • Individual Member Benefits
      • Institutional Program Member Benefits
      • Sustaining Associate Member Benefits
      • Get Involved at SfN
    • Become a Member
      • Sponsorship Information for New Members
      • Membership Categories & Fees
      • Membership Fees for Developing Countries
      • Renew Individual Membership
    • Member Resources
      • Automatic Renewals
      • Frequently Asked Questions
      • Individual Member Directory
      • Member Obituaries and Memorial Donations
    • Learn About Local Chapters
      • Start or Reactivate a Chapter
      • Resources for Chapters
      • Submit Annual Report
      • Chapter Directory
      • Frequently Asked Questions
  • Meetings
    • Meetings Overview
    • Neuroscience 2026
      • Dates and Deadlines
      • Exhibits
      • Housing and Travel
      • Call for Abstracts
      • Sessions and Events
      • Registration
      • Advertising and Sponsorship
      • FAQs
    • Global Events
      • SfN Virtual Events
    • Past and Future Annual Meetings
      • Neuroscience 2025
      • Neuroscience 2024
      • Search Past Annual Meeting Abstracts
      • Attendance Statistics
    • Meeting Policies and Guidelines
      • Code of Conduct at SfN Events
      • Growth and Opportunity Strategy
      • Photography & Recording Policy
      • Presenter Guidelines and Policies for SfN Events
    • Meeting Awards
      • Trainee Professional Development Award
      • International Travel Awards
      • FENS Member Awards to SfN Annual Meeting
      • IBRO Member Awards to SfN Annual Meeting
      • JNS Member Awards to SfN Annual Meeting
  • Careers
    • Careers Overview
    • Institutional Program (IP) Directory
    • NeuroJobs Career Center
      • Job Seekers
      • Employers
    • 2025 Graduate School Fair
    • Career Tools and Resources
      • Neuronline
      • Neurobiology of Disease Workshop
      • Responsible Conduct of Research Short Courses
      • Neuroscience Departments and Program Workshop
      • Global Funding Sources
    • Higher Education and Training
      • Core Competencies
      • Neuroscience Training Program Survey
    • Awards
      • Outstanding Career and Research Achievements
      • Early Career
  • Initiatives
    • Initiatives Overview
    • Awards
      • 2025 Award Recipients
      • Awards and Prizes FAQ
      • Trainee Professional Development Award
    • Neuroscience Scholars Program
    • Neuronline
      • Webinars
      • Articles
      • Videos
      • Podcasts
      • Collections
    • Resources to Stay Connected
      • SfN Zoom Backgrounds
    • Community
    • Women and Neuroscience
      • Increasing Women in Neuroscience (IWiN) Courses & Toolkit
      • Celebration of Women in Neuroscience Event
      • Awards
    • Animals in Research
      • Support for Members and Institutions
      • Tools and Resources
      • Resources for Medical Students
    • Public Education Programs
      • Resources for Educators
      • Brain Awareness Video Contest
      • Life of a Neuron Exhibit
  • Advocacy
    • Advocacy Overview
    • Advocacy Response
    • Advocacy Network
      • The NeuroAdvocate Challenge
      • Advocacy Action Center
      • Advocacy Best Practices
      • Advocacy Network News
      • Advocacy Training Seminars
    • US Advocacy Programs
      • Capitol Hill Day
      • Connect with Policymakers
      • Early Career Policy Ambassadors
      • Partner with a Local Chapter
      • Engage the Media
    • Global Advocacy Programs
      • Global Neuroscience Initiatives
      • Global Funding
      • North American Programs
    • Science Funding
      • Advocacy Videos
      • Advocacy Resources
      • US Neuroscience Initiatives
      • Funding Priorities and Processes
    • Policy Positions
      • Statements and Testimony
      • Sign-On Letters
  • Outreach
    • Outreach Overview
    • BrainFacts.org
    • Find a Neuroscientist
    • Brain Awareness Campaign
      • Webinar: The ABC's of BAW
      • How to Get Involved
    • Awards
      • Award for Education in Neuroscience
      • Next Generation Award
      • Chapter of the Year Award
      • Science Educator Award
  • Publications
    • Publications Overview
    • SfN News
    • JNeurosci
    • eNeuro
    • SfN Nexus
    • Neuroscience Quarterly
    • Annual Report
    • History of Neuroscience Autobiographical Chapters
  • About
    • About Overview
    • Mission and Strategic Plan
    • What We Do
      • Annual Report
      • Bylaws
      • Resolutions to the Bylaws
      • Environmental Commitment
      • Strategic Partners
      • History of SfN
    • SfN 50th Anniversary Celebration
    • NIH Public Health Service-Supported Funding Financial Conflict of Interest Policy
    • Volunteer
      • SfN Council
      • SfN Presidents
      • Committees
      • Elections
      • Call for Nominations
    • Professional Conduct
      • SfN Ethics Policy
      • Guidelines for Responsible Conduct Regarding Scientific Communication
      • Code of Conduct at SfN Events
      • Commitment to Scientific Integrity
      • Neuronline Digital Learning Community Guidelines
    • History of Neuroscience
      • Autobiographical Chapters
      • Autobiographical Videos of Prominent Neuroscientists
      • Classic Papers
      • Neuroscience History Resources
      • Robert Doty's Chapter on Neuroscience
    • Careers and Staff
      • Staff List
  1. Search

Filter

  • (1)
  • (1)
  • (4)
  • (74)
  • (4)
Filter
41 - 50 of 109 results
  • Abstract
    A low dose of delta-9-tetrahydrocannabinol (THC) enhances sucrose palatability when administered 120-min, but not 30- or 60-min, prior to a taste reactivity test.
    Considerable anecdotal reports suggest that marijuana enhances palatability, however there has been little direct experimental evidence for these claims. The taste reactivity (TR) test is a direct measure of palatability in rats. The taste reactivity (TR) test was used to evaluate the potential of THC to modify sucrose palatability as measured by the frequency of tongue protrusions. On each of the 9 test trials, rats were injected with either THC (0.5 mg/kg) or vehicle 30, 60 or 120 minutes prior to receiving a 5 min intraoral infusion of 2%, 10% and 32% sucrose solution. The TR test revealed that at 120 min post-injection THC increased the palatability of sucrose solution, regardless of the concentration. Current experiments are investigating the effects of THC on quinine palatability using the TR test.
    Oct 25, 2004
  • Abstract
    Effects of THC and SR-141716 on timing behavior in rats.
    The effects of marijuana and THC on time perception are well documented. Yet, little is known about the mechanisms that underlie these effects. The present series of experiments examined the effects of THC (0.01-5.0 mg/kg) and of the CB-1 antagonist SR-141716 (0.01-3.0 mg/kg) using a 10-14 second temporal response differentiation schedule in male Sprague-Dawley rats. Under this schedule, subjects were required to make a continuous response on an operant lever for at least 10, but not more than 14 seconds. Releasing the lever within this 10-14 second window resulted in food pellet delivery. Failure to release the lever within this 10-14 second window had no programmed consequences. Acute administration of SR-141716 shifted the distribution of response durations to the right, perhaps suggesting a slowing of the internal timer. In a separate experiment, acute administration of THC produced a generalized disruption in task performance but did not systematically alter the distribution of TRD response durations....
    Nov 9, 2000
  • Abstract
    Dose-related effects of Δ9-tetrahydrocannabinol on local cerebral glucose utilization.
    Recent reports have shown that Δ9-tetrahydrocannabinol (THC) stimulates locomotor activity at low doses (≤2.0 mg/kg), while higher doses (>2.0 mg/kg) produce decreases in spontaneous activity. Using quantitative [14C]2-deoxyglucose (2-DG) autoradiography we have systematically studied the effects of acute Δ9-tetrahydrocannabinol in these dose ranges on rates of local cerebral glucose utilization. The present series of experiments was designed to determine if THC-mediated changes in cerebral metabolism followed a clear dose-response relationship. Adult male Sprague-Dawley rats were treated with either vehicle or THC (0.25, 1.0, or 2.5 mg/kg, i.p.) and the 2-DG procedure was initiated 15 min following exposure. Administration of 2.5 mg/kg THC produced significant decreases in cerebral metabolism in most brain regions studied. In contrast, administration of the two lower doses (0.25, 1.0 mg/kg) of THC produced more restricted effects on metabolism. Significant decreases in metabolism were limited to anterior ...
    Nov 7, 2000
  • Cannabidiol Targets Mitochondria to Regulate Intracellular Ca2+ Levels | Journal of Neuroscience
    Cannabinoids and the endocannabinoid system have attracted considerable interest for therapeutic applications. Nevertheless, the mechanism of action of one of the main nonpsychoactive phytocannabinoids, cannabidiol (CBD), remains elusive despite potentially beneficial properties as an anti-convulsant and neuroprotectant. Here, we characterize the mechanisms by which CBD regulates Ca2+ homeostasis and mediates neuroprotection in neuronal preparations. Imaging studies in hippocampal cultures using fura-2 AM suggested that CBD-mediated Ca2+ regulation is bidirectional, depending on the excitability of cells. Under physiological K+/Ca2+ levels, CBD caused a subtle rise in [Ca2+]i, whereas CBD reduced [Ca2+]i and prevented Ca2+ oscillations under high-excitability conditions (high K+ or exposure to the K+ channel antagonist 4AP). Regulation of [Ca2+]i was not primarily mediated by interactions with ryanodine or IP3 receptors of the endoplasmic reticulum. Instead, dual-calcium imaging experiments with a cytosoli...
    Feb 18, 2009 Duncan Ryan
  • Abstract
    The effects of cannabidiol in a kainate model of temporal lobe epilepsy.
    Cannabinoids, including cannabidiol (CBD), a non-psychoactive component of cannabis sativa, have been shown to exhibit anticonvulsant properties in animal models of epilepsy (Wallace et al. 2001; 2003). To investigate cannabinoid-mediated seizure control, CBD was compared to the synthetic CB1 receptor agonist HU-210 in a rat model of kainate-induced temporal lobe seizures (TLS) in vivo. Multiple single-unit and local field potentials (LFPs) were recorded from the hippocampus of male Sprague Dawley rats (200-300g) anaesthetised with urethane (1.3g kg-1 i.p.) or isoflurane/N2O/O2 using 16-channel micro-wire electrodes (NB Labs) and a Plexon Map system. Kainate (KA: 10mg kg-1), cannabidiol (10 or 40mg kg-1) or HU-210 (100μg kg-1) were administered i.p. Data was analysed with Neuroexplorer, including firing frequency, burst analysis, T50 for KA-induced effects, and LFP power spectral density (PSD). While CBD reduced basal firing in ∼20% of cells, CBD did not alter KA-induced firing administered before (n=63 ce...
    Nov 15, 2005
  • Abstract
    Differences in regional brain function due to marijuana use by methamphetamine abusers.
    Most studies of human drug abuse highlight dependence on one primary agent without explicitly considering use of other psychoactive agents such as marijuana (MJ). We previously showed regional cerebral dysfunction in methamphetamine (MA) abusers, particularly in limbic/paralimbic areas, and now assess the combined effects of MJ and MA on cerebral function. We studied 14 MA abusers who reported MA as their drug of choice, had on average used MA for >8 years, and used it on most of the 30 days prior to entering the study. We separated this sample into one group of subjects who reported no substantial drug use other than MA abuse (-MJ, n=7), and another group of subjects who either used MJ frequently (>1 joint/wk) or met DSM-IV criteria for THC dependence (+MJ,n=7). Both groups abstained from all illicit drug use for 5–11 days before assay of global and regional cerebral glucose metabolism (CMRglc, rCMRglc) with PET during performance of an attentional task. The +MJ group had 6% lower CMRglc than the -MJ grou...
    Nov 10, 2003
  • Abstract
    Previous exposure to δ9-THC does not promote the pursuit of amphetamine.
    Rats previously exposed to amphetamine (AMPH) show enhanced locomotor and nucleus accumbens (NAcc) dopamine (DA) responding to the drug as well as enhanced self-administration of AMPH and cocaine. The present experiments assessed the effects of pre-exposing rats to Δ9-THC. Rats in different groups were given five pre-exposure injections of saline or one of five doses of Δ9-THC (0.4, 0.75, 1.5, 3.0, 6.0 mg/kg, IP), one injection every third day, and tested two to three weeks later. Previous exposure to all but the lowest dose of Δ9-THC enhanced the locomotor response to AMPH (0.75 mg/kg, IP) but all failed to enhance NAcc DA overflow in response to AMPH. Previous exposure to 3.0 mg/kg (IP, the most effective Δ9-THC dose above) also enhanced forskolin-evoked adenylyl cyclase activity in the NAcc and rats’ locomotor response to the direct DA receptor agonist apomorphine (1.0 mg/kg, SC), suggesting that previous exposure to Δ9-THC enhances locomotor responding to AMPH by up-regulating postsynaptic DA receptor ...
    Nov 8, 2003
  • Abstract
    Intracranial Self-Administration and Psychomotor Stimulant Effects of Delta-9-Tetrahydrocannabinol.
    Delta-9-tetrahydrocannabinol (THC) is the most widely abused illicit drug and its reinforcing properties have been demonstrated in animal models. However, the brain regions that are involved in the reinforcing effects of THC have not been identified yet. In the present study we investigated the rewarding and psychomotor stimulant effects of THC in several discrete brain sites. We found that rats would learn to lever-press for microinjections of THC directly into the posterior ventral tegmental area (VTA). Lever-pressing for THC in the posterior VTA was extinguished when vehicle was substituted for the drug, and was reinstated when THC reinforcement was re-established. Rats did not learn to lever-press for microinjections of THC into the anterior VTA or into a region dorsal to the posterior VTA. Injection of THC into the posterior VTA induced a moderate increase in the locomotor activity, while injections into the anterior or dorsal to VTA did not affect locomotion. The effects of THC in the nucleus accumbe...
    Nov 7, 2002
  • Abstract
    Inhibitory function and white matter changes in chronic marijuana smokers: a DTI study.
    Abnormalities in executive function and the ability to successfully monitor and inhibit inappropriate behaviors have been reported in substance abusing individuals. Recent investigations which have utilized neuroimaging and neurocognitive techniques to evaluate frontal systems in heavy cannabis smokers have reported alterations during inhibitory tasks which require frontal processing. Diffusion tensor imaging (DTI) methods provide a quantitative estimate of white matter integrity, providing new insight at the microstructural level. We applied diffusion tensor imaging techniques (DTI) and a brief neurocognitive battery which included measures of frontal/executive function to examine the relationship between frontal white matter changes and neuropsychological performance in nine heavy cannabis smokers and 9 matched control subjects. DTI data were acquired on a 3.0 Tesla scanner using a diffusion weighted twice-refocused spin echo EPI sequence. Voxels (11cm3) were placed in the midline of the splenium of the ...
    Nov 16, 2005
  • Abstract
    Modulation of δ9-THC-induced ataxia by mouse cerebellar nicotinic--cholinergic receptor subtype.
    No study regarding effects of Δ9-THC and nicotine co-administration on motor functions is known. Therefore, it was interesting to investigate functional consequences of intracerebellar (ICB) microinfusion of nicotine on ICB Δ9-THC-induced ataxia. Cerebellum was selected because of its established role in Δ9-THC-induced ataxia. Using the Rotorod, the effect of direct ICB microinfusion of various doses of nicotine [5, 2.5,1.25ng] on Δ9-THC [20 µg]-induced ataxia was investigated. There was a significant (p<0.05) attenuation by ICB nicotine on Δ9-THC-induced ataxia in a dose-related manner. The highest nicotine dose (5 ng) virtually abolished the Δ9-THC-induced ataxia. ICB pretreatment with nicotine antagonist hexamethonium (1µg) significantly blocked nicotine’s ability to attenuate Δ9-THC-induced ataxia suggesting that a nicotine - Δ9-THC behavioral interaction involved participation of nAChR. To further elucidate specific subtype of nicotinic receptor involved in the attenuation of Δ9-THC-induced ataxia, di...
    Nov 15, 2005
  • Previous
  • 3
  • 4
  • 5
  • 6
  • 7
  • Next

Featured

  • Explore the benefits of an SfN membership
  • Upcoming Webinar: Behavioral and Evolutionary Adaptations to Changing Environments
  • Seeburg Prize nominations have been extended to February 19
SfN Websites
  • BrainFacts.org logo
  • eNeuro logo
  • JNeurosci logo
  • Neuronline logo
Engage with SfN
  • join Join
  • give Give
  • advocate Advocate
  • publish Publish
Quick Links
  • SfN News
  • For Press
  • Global Events
  • Contact Us
  • Advertise
  • Code of Conduct
  • Jobs at SfN
  • SfN Store
  • Social Media
Follow SfN
  • BlueSky logo
  • Facebook logo
  • Instagram logo
  • LinkedIn logo

  • Threads logo
  • X Logo
  • YouTube logo
SfN logo with "SfN" in a blue box next to Society for Neuroscience in red text and the SfN tag line that reads "Advancing the understanding of the brain and nervous system"
1121 14th Street NW, Suite 1010, Washington, D.C. 20005
(202) 962-4000 | 1-888-985-9246
  • Accessibility Policy
  • Disclaimer
  • Privacy Notice
  • Contact Us

Copyright ©
Society for Neuroscience